Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Queensland Health
UBS
Boehringer Ingelheim
Mallinckrodt
Teva
Julphar
Citi
Moodys
Daiichi Sankyo

Generated: October 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,303,651

« Back to Dashboard

Summary for Patent: 4,303,651

Title: Heparin fragments having selective anticoagulation activity
Abstract:Heparin fragments having selective anticoagulation activity having 14-18 sugar units, the disaccharide unit L-iduronosyl-2-O-sulphate-N-sulpho-U-glucosamine-6-O-sulphate being the main component, and where unsulphated L-iduronic acid is in a position situated 3-5 sugar units from the unreducing terminal. Pharmaceutical compositions containing such heparin fragments. Processes for the preparation of the heparin fragments.
Inventor(s): Lindahl; Ulf P. F. (Uppsala, SE), Backstrom; Gudrun E. (Alunda, SE), Thunberg; John Y. L. (Uppsala, SE), Fransson; Lars-Ake (Lund, SE), Andersson; Lars-Olov (Knivsta, SE), Holmer; Erik Y. (Bromma, SE), Sandberg; Inga H. (Sollentuna, SE), Soderstrom; Ewa G. (Saltsjobaden, SE)
Assignee: Kabi AB (Stockholm, SE)
Application Number:06/109,936
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

No matches for this query

Foreign Priority and PCT Information for Patent: 4,303,651

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden7900164Jan 08, 1979

International Patent Family for Patent: 4,303,651

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria8998► Subscribe
Canada1136620► Subscribe
Germany3068924► Subscribe
Denmark160764► Subscribe
Denmark380280► Subscribe
European Patent Office0014184► Subscribe
JapanS56500066► Subscribe
JapanS6344764► Subscribe
Netherlands930104► Subscribe
Norway150801► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Novartis
UBS
Federal Trade Commission
Daiichi Sankyo
Express Scripts
Covington
Cipla
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot